Alzheimer Disease

There are many factors that make living at home with Alzheimer disease difficult.

A panel discussion on a growing public concern over our ability to treat and prevent dementia.

The aim of the “Alzheimer’s Disease Exposome” will be to identify new interactions of risk genes for future studies.

Acadia Pharmaceuticals has announced positive findings for time to psychosis relapse in dementia patients, which resulted in the trial's early end.

Benzodiazepines are a common yet not very well understood drug class for elderly patients with insomnia.

Using a variety of tests to measure cognitive changes, investigators find that gender and education level does not impact cognitive decline as much as health and lifestyle factors.

Findings from the Insight 46 study reveal blood pressure changes during midlife can lead to poorer brain health as a patient gets older.

The association of depression symptoms with cognition and cortical amyloid measurements could lead to better therapies to prevent Alzheimer disease.

Considerations for improving upon the diagnosis and management of Alzheimer disease.

Alkahest announces positive top-line data for phase 2 study to treat mild-to-moderate Alzheimer disease.

Socially active people in the their 50s and 60s have a lower risk of developing dementia, according to a new study.

New model predicts patients at risk of developing Alzheimer disease up to 2 years in the future.

An overview of exciting, upcoming therapies that may be of interest for the treatment of Alzheimer disease.

Experts discuss the status of clinical trials that explore various monoclonal antibody therapies and BACE inhibitors for the treatment of Alzheimer disease.

New study links serum-based liver function markers with known Alzheimer disease biomarkers.

The rationale for investigating monoclonal antibodies and BACE inhibitors for the treatment of patients with Alzheimer disease.

The International Congress on the Future of Neurology will take place this Fall in New York City, convening experts in neurology to discuss the latest data and best practices to better inform clinical decision-making.

Drs. Alireza Atri and Ronald C. Petersen remark on the important roles a community neurologist, as well as other members of a patient’s health care team, can play in the management of Alzheimer disease.

The fourth version of the Cleveland Clinic’s Alzheimer pipeline includes 156 clinical trials and 132 agents currently in all 3 phases of clinical trials in the US.

The role of clinical trials and the importance of counseling patients on trial enrollment and lifestyle interventions in the management of Alzheimer disease.

Expert clinicians highlight current unmet needs surrounding the treatment of Alzheimer disease.

Older patients could benefit from skipping traditional bedrest in favor of an exercise program when hospitalized with an acute illness.

Moving forward following failed studies in Alzheimer disease and improving how the condition is managed in the future.

An in-depth review of mechanisms linked to the pathogenesis of Alzheimer disease, including amyloid and tau.

Ronald C. Petersen, MD, PhD, discusses the relationship between genetics and the risk for developing Alzheimer disease, as well as highlights efforts of the Generation Program.

How improved telemedicine options could benefit the geriatric patient population and others who may not actually be suitable for emergency care situations.

How the thought of AD has changed to interpret the disease's pathology, and why that has benefitted clinicians.

AD symptoms can take years to manifest, making clinical trials difficult. Investigators are fixed on finding disease biomarkers.

What new drug classes are catching the most traction among clinicians?